

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. 1)

**Cytori Therapeutics, Inc.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**23283K204**

(CUSIP Number)

**December 31, 2017**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**Item 1.**

- (a) Name of Issuer  
Cytori Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices  
3020 Callan Road  
San Diego, CA 92121

**Item 2.**

- (a) Name of Person Filing  
Azaya Therapeutics, Inc.
- (b) Address of Principal Business Office or, if none, Residence  
250 W. Nottingham, Suite 120  
San Antonio, TX 78209
- (c) Citizenship  
Unites States
- (d) Title of Class of Securities  
Common Stock
- (e) CUSIP Number  
23283K204

**Item 3. If this statement is filed pursuant to Secs. 240.13d-1(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

- (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) o An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);
- (f) o An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);
- (g) o A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);
- (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) o Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J).

2

---

**Item 4. Ownership.**

(a) Amount beneficially owned  
293,310

---

(b) Percent of class  
1.2

---

(c) Number of shares as to which such person has:

---

(i) Sole power to vote or to direct the vote  
293,310

---

(ii) Shared power to vote or to direct the vote  
none

---

(iii) Sole power to dispose or to direct the disposition  
293,310

---

(iv) Shred power to dispose or to direct the disposition of  
none

---

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being reported on By the Parent Holding Company.**

Not applicable

**Item 8. Identification and Classification of Members of the Group.**

Not applicable

**Item 9. Notice of Dissolution of the Group.**

Not applicable

3

---

**Item 10. Certifications.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 4, 2018

AZAYA THERAPEUTICS, INC.

By: /s/ John C. Kerr

Name: John C. Kerr

Title: President